Medical Advocates
Darunavir(Prezista/TMC-114) |
Last
Update:
September 13, 2016
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
Pediatric data are indexed in the
pediatric section
XX International AIDS Conference
|
-
Darunavir (DRV)/r-based
Postexposure Prophylaxis (PEP) versus standard of care (SOC) - quality of
life in patients receiving PEP in a randomized study (PEPDar)
H. Jessen, T. Kümmerle, A.B. Jessen, et al
Abstract
-
Comparison of
effects of atazanavir, raltegravir, or darunavir with FTC/tenofovir on
biomarkers of systemic inflammation, macrophage and T cell activation: ACTG
A5260s
T. Kelesidis T.T.T. Tran, G.A. McComsey, et al
Abstract
-
DRIVESHAFT study:
switching from twice-daily darunavir/ritonavir (DRV/r) to once-daily DRV/r
in virologically-suppressed treatment-experienced HIV-infected patients
maintains
virologic suppression and improves antriretroviral adherence and LDL
cholesterol
G. Huhn, A. Sigman, B. Livak, et al
Abstract
-
HCV co-infection
does not compromised darunavir monotherapy efficacy in HIV-infected
patients, though induce higher immune activation profiles
O.-J. Ben-Marzouk Hidalgo, A. Torres-Cornejo, A. Gutiérrez-Valencia, et al
Abstract
-
Outcomes of Botswana´s highly treatment experienced adults on raltegravir
and darunavir containing ART regimens at Princess Marina Hospital in
Gaborone
A. Avalos, M. Haverkamp, V. Letsatsi, et al
Abstract
XIX International AIDS Conference
|
A. Torres-Cornejo, R. Martin-Peña, O. Ben-Marzouk Hidalgo, et al
Abstract
Darunavir/r once
daily in treatment-naïve adolescents: 48-week results of the DIONE study
C. Giaquinto, P. Flynn, S. Blanche, et al
Abstract
Outcomes of
third-line antiretroviral therapy containing darunavir, etravirine or
raltegravir in Thai children with HIV infection
J. Ananworanich,, W. Prasitsuebsai, P. Kosalaraksa, et al
Abstract
Horizontal
transmission of HIV-1 exhibiting resistance to four antiretroviral drug
classes, including integrase inhibitors
C. Walworth, D. Ward, L. Napolitano, et al
Abstract
Treatment
optimization in HIV-2-positive patients
P. Andrade, J. Soares, C. Caldas, et al
Abstract
Steady-state pharmacokinetic interactions of darunavir/ritonavir with
pitavastatin in healthy adult volunteers
C.Y. Yu, S.E. Campbell, C.A. Sponseller, et al
Abstract
| |
XX
IAC
Darunavir Main Page
Main
New/Newsworthy